- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00611000
Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia
Effect of Folate on Colonic and Blood Cells
RATIONALE: Studying samples of blood and tissue from patients at risk of cancer in the laboratory may help doctors learn more about the effect of folate on DNA and identify biomarkers related to cancer.
PURPOSE: This phase I trial is studying the effect of folate on DNA in colon tissue and peripheral blood samples from patients at increased risk of developing colorectal neoplasia.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES:
- To analyze the effects of changes in levels of dietary folate intake on damage to DNA and repair capacity, mRNA expression, and DNA uracil incorporation in peripheral blood mononuclear cell and rectal biopsy cell samples from patients at increased risk for developing colorectal neoplasia.
OUTLINE: Patients are enrolled into 1 of 2 intervention groups..
- Group I (folate depletion [in-patient]): Patients consume a weight-maintaining, average folate diet with no high folate-containing foods for 8 weeks. Patients are then admitted to The Rockefeller University Hospital and placed on a weight-maintaining, low-folate diet for 12 weeks. During the last 4 weeks of the in-patient period, patients receive oral folic acid supplementation once daily for 4 weeks.
- Group II (folate supplementation [out-patient]): Patients consume a weight-maintaining, average folate diet with no high folate-containing foods for 16 weeks as an out-patient. After the first 8 weeks of the diet, patients also receive oral folic acid supplementation once daily for 8 weeks.
Patients undergo blood sample collection periodically for biomarker correlative studies. Samples are analyzed for serum and red cell folate and homocystine levels to assess folate depletion; methylentetrahydrofolate reductase (MTHFR) polymorphism to test for inherited alterations of folate metabolism; serum and plasma biomarkers; and DNA studies. Patients also undergo tissue sample collection by sigmoidoscopy and rectal biopsy periodically. Tissue samples are assessed for mucosal folate concentration and mucosal folic acid metabolites; DNA methylation; and gene assays by microarray analysis.
After completion of study intervention, patients are followed at 4 weeks.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 1
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
At increased risk for developing colorectal neoplasia due to 1 of the following:
- Personal history of colorectal adenomatous polyps
- Family history of colorectal adenoma or adenocarcinoma
- No hereditary nonpolyposis colorectal cancer (HNPCC)
- No more than one first-degree family member with colorectal or endometrial malignancies
PATIENT CHARACTERISTICS:
- Ambulatory
- Female patients must be ≥ 2 years post-menopausal (i.e., 2 years after the last menstrual period)
- Negative pregnancy test
- Male patients must use effective contraception during and for 2 months after completion of study treatment (for male patients enrolled in the folate depletion group)
- Serum folate level ≤ 20 ng/mL
- Plasma vitamin B12 level ≥ 250 pg/mL
- Serum homocysteine level ≤ 17 μmol/L
- ALT or AST ≤ 2 times upper limit of normal
- No unexplained elevated alkaline phosphatase
- Creatinine ≤ 2.0 mg/dL
- HIV negative
- No folate metabolism abnormalities or predisposing conditions
- No prior malignancy except nonmelanoma skin cancer
- No intestinal malabsorption or inflammatory bowel disease
- No excessive bleeding or coagulation disorder
- No untreated hyperthyroidism
- No diabetes mellitus requiring insulin
- No daily alcohol intake > 2 ½ shot glasses of whisky or three 8-ounce glasses of beer or wine
- No sustained blood pressure > 150/95 mm Hg for three consecutive readings
- No other serious illness that would limit life expectancy to < 6 months
PRIOR CONCURRENT THERAPY:
No prior gastrointestinal surgery, including gastrectomy or small or large bowel resections
- Prior appendectomy or surgery of the esophagus allowed
More than 3 months since regular ingestion of ≥ 650 mg of aspirin (≥ 2 tablets of 325 mg regular strength OR > 1 tablet of 500 mg extra strength aspirin) per day
The following drugs are allowed for cardiovascular prophylaxis provided the patient has been taking the drug regularly for ≥ 1 month and continues to take the same dose during study participation:
- One or two regular strength aspirin tablets (i.e., 325 mg per tablet) per day
- One baby aspirin tablet (81 mg tablet) per day
- More than 3 months since regular daily ingestion of other non-steroidal anti-inflammatory drugs (NSAIDs)
- No concurrent anticoagulation therapy
- No concurrent sterol-binding resins, such as cholestyramine (for the treatment of high blood cholesterol)
- No other concurrent investigational drugs
- No other concurrent medications that might, in the view of the study physicians, alter rectal mucosal proliferation, folate metabolism, or renal/hepatic metabolism
- No concurrent weight control medications
- No concurrent supplemental folate preparation containing > 400 mcg of folic acid per day
No concurrent hormone replacement therapy, including oral, transplanted, or injected contraceptives
- Concurrent thyroid hormone replacement allowed provided the patient is euthyroid
No concurrent medication interfering with folic acid metabolic effects, including any of the following:
- Methotrexate
- Phenytoin
- Phenobarbital
- Primidone
- Sulfonamides
- Folinic acid derivatives
No concurrent lipid-lowering medications other than usual doses of the class of drugs known as statins
The following statin drugs are allowed provided the patient has been taking the drug regularly for ≥ 1 month and continues to take the same dose during study participation:
- Atorvastatin (10 or 20 mg/day)
- Fluvastatin (20 mg or 40 mg/day)
- Lovastatin (10 or 20 mg/day)
- Pravastatin (10 or 20 mg/day)
- Simvastatin (5 or 10 mg/day)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Enmascaramiento: Único
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
DNA uracil incorporation in peripheral blood mononuclear cells (PBMCs)
|
Strand breaks in the coding region of p53 in PBMCs and rectal biopsy cells
|
DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells
|
Medidas de resultado secundarias
Medida de resultado |
---|
Differential gene expression in colonic and PBMCs by microarray analysis
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Peter R. Holt, MD, Rockefeller University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Efectos fisiológicos de las drogas
- Micronutrientes
- Vitaminas
- Complejo de vitamina B
- Hematínicos
- Ácido fólico
Otros números de identificación del estudio
- CDR0000582113
- RUH-PHO-0514-0306
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer colonrectal
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Xinhua Hospital, Shanghai Jiao Tong University...Aún no reclutandoCANCER DE PROSTATA | Biopsia de próstataPorcelana
Ensayos clínicos sobre análisis de expresión génica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
The Center for the Biology of Chronic DiseaseTerminadoInfecciones por el virus de Epstein-Barr | Infecciones por citomegalovirus | Virus del papiloma humano | Infecciones por herpes simple | Infección por el virus de la varicela zósterEstados Unidos
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Witwatersrand, South Africa; PD Hinduja Hospital and Medical Research... y otros colaboradoresTerminadoTuberculosis Pulmonar | Tuberculosis resistente a múltiples fármacosMoldavia, República de
-
Kessler FoundationTerminadoDesorden del espectro autista | Autismo | TEAEstados Unidos
-
Assiut UniversityTerminado
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Michigan State UniversityReclutamientoSepticemia | Síndrome de Respuesta Inflamatoria Sistémica | Infección Bacteriana | Infección, Coronavirus | Infección, Hongos | Infección MixtaEstados Unidos
-
Tanta UniversityTerminado